BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc. (Profectus), a biopharmaceutical company that develops proprietary prime/boost vaccines and small molecule to treat and prevent viral infections and cancers, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) has awarded to Profectus via a Novation Agreement, two contracts (HHSN272200800061C and HHSN272200800062C) totaling $21.6 million to develop a preventative HIV vaccine delivered with the Company’s recombinant vesicular stomatitis virus (rVSV) vector and a therapeutic HIV DNA based vaccine. The contracts were awarded to Profectus under NIAID’s HIV Vaccine Design and Development Teams program.
